aTyr Pharma (ATYR) Projected to Post Earnings on Wednesday

aTyr Pharma (NASDAQ:ATYR) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect aTyr Pharma to post earnings of ($0.16) per share for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. On average, analysts expect aTyr Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

aTyr Pharma Stock Performance

Shares of ATYR opened at $0.83 on Monday. aTyr Pharma has a 1 year low of $0.64 and a 1 year high of $7.29. The company’s 50 day simple moving average is $0.86 and its 200 day simple moving average is $0.82. The company has a market capitalization of $81.72 million, a price-to-earnings ratio of -1.06 and a beta of 0.66.

Analysts Set New Price Targets

A number of research analysts have weighed in on ATYR shares. Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.67.

Institutional Trading of aTyr Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in ATYR. California State Teachers Retirement System acquired a new position in aTyr Pharma in the second quarter valued at $28,000. Legal & General Group Plc purchased a new position in shares of aTyr Pharma in the 2nd quarter worth about $49,000. Prudential Financial Inc. purchased a new position in shares of aTyr Pharma in the 2nd quarter worth about $63,000. Oxford Asset Management LLP acquired a new position in shares of aTyr Pharma in the 2nd quarter valued at about $70,000. Finally, Creative Planning acquired a new position in shares of aTyr Pharma in the 2nd quarter valued at about $74,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.